Stockreport

Roivant Sciences: Brepocitinib And Roadmap Still Underpriced [Seeking Alpha]

Roivant Sciences Ltd.  (ROIV) 
PDF ROIV focuses on autoimmune and rare-disease drug programs. Recent promising Phase 3 data for DM with Brepocitinib have helped the stock appreciate. Brepocitinib could [Read more]